Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials

Stroke

Volumn 47, Issue 9, 2016, Pages 2373-2379

  Lees, Kennedy R ^a   Emberson, Jonathan ^b   Blackwell, Lisa ^b   Bluhmki, Erich ^c   Davis, Stephen M ^d   Donnan, Geoffrey A ^d   Grotta, James C ^e   Kaste, Markku ^f   Von Kummer, Rüdiger ^g   Lansberg, Maarten G ^h   Lindley, Richard I ⁱ   Lyden, Patrick ^j   Murray, Gordon D ^k   Sandercock, Peter A G ^k   Toni, Danilo ^l   Toyoda, Kazunori ^m   Wardlaw, Joanna M ^k   Whiteley, William N ^k   Baigent, Colin ^b   Hacke, Werner ⁿ   Howard, George ^o   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MEMORIAL HERMANN HOSPITAL   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h Stanford Medicine Children s Health   (United States)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

confidence interval; odds ratio; stroke; thrombolytic therapy; United States

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE DISTRIBUTION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY RISK; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL STATUS; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL PREDICTION; THERAPY DELAY; TIME TO TREATMENT; BRAIN ISCHEMIA; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84981275853     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.013644     Document Type: Article

References (20)

1. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178. doi: 10.1161/STROKEAHA.111.641456.
2. Emberson J, Lees KR, Lyden P, Albers G, Bluhmki E, Brott T, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;379:2352-2363.
3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703. doi: 10.1016/S0140-6736(10)60491-6.
4. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
5. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833. doi: 10.1161/ STROKEAHA.109.561365.
6. Dawson J, Lees JS, Chang TP, Walters MR, Ali M, Davis SM, et al; GAIN and VISTA Investigators. Association between disability measures and healthcare costs after initial treatment for acute stroke. Stroke. 2007;38:1893-1898. doi: 10.1161/STROKEAHA.106.472381.
7. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al; European Stroke Organization Outcomes Working Group. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012;43:1163-1170. doi: 10.1161/ STROKEAHA.111.641423.
8. Rahlfs VW, Zimmermann H, Lees KR. Effect size measures and their relationships in stroke studies. Stroke. 2014;45:627-633. doi: 10.1161/ STROKEAHA.113.003151.
9. Stroke Thombolysis Trialists' Collaboration. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative metaanalysis. Int J Stroke 2013;8:278-283.
10. McCullagh P. Regression models for ordinal data (with discussion). J R Statist Soc B. 1980;42:109-142.
11. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, et al. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke. 2012;43:664-669. doi: 10.1161/STROKEAHA.111.632935.
12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
13. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
14. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
16. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
17. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309. doi: 10.1016/S1474-4422(08)70044-9.
18. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al; The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST- 3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
19. Whiteley WN, Emberson J, Lees KR, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg MG, Lindley RI, Lyden P, Olivot JM, Parsons M, Toni D, Toyoda K, Wahlgren N, Wardlaw J, del Zoppo GJ, Sandercock P, Hacke W, Baigent C. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15:925-933. doi: 10.1016/S1474-4422(16)30076-X.
20. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis. 2008;25:457-507.